Merck's Bridion Approval Carries Several Post-Market Requirements
This article was originally published in The Pink Sheet Daily
Merck must conduct studies to determine likely non-responders, assess occurrence of hypersensitivity or anaphylaxis, evaluate risk of cardiac arrhythmias, and study sugammadex's effects in morbidly obese patients.
You may also be interested in...
FDA officials question whether modeling tools can predict which drugs have different disposition in obese populations. They say physiologically-based pharmacokinetic data cannot be used as a surrogate for actual clinical trial data at this time.
Advisory committee suggests post-marketing epidemiological studies in higher risk patients to further assess risks of hypersensitivity, anaphylaxis and cardiac rhythm disorders with the neuromuscular blockade reversal agent.
People have challenged patent listings more than 60 times in the past six years but it is up to new drug application holders to decide whether to revise or delist their submissions.